Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 3;8(7):676.
doi: 10.3390/cells8070676.

Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer

Lucile Broncy  1 , Patrizia Paterlini-Bréchot  2   3
Affiliations
Review

Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer

Lucile Broncy et al. Cells. .

Abstract

The main issue concerning localized prostate cancers is the lack of a suitable marker which could help patients' stratification at diagnosis and distinguish those with a benign disease from patients with a more aggressive cancer. Circulating Tumor Cells (CTC) are spread in the blood by invasive tumors and could be the ideal marker in this setting. Therefore, we have compiled data from the literature in order to obtain clues about the clinical impact of CTC in patients with localized prostate cancer. Forty-three publications have been found reporting analyses of CTC in patients with non-metastatic prostate cancer. Of these, we have made a further selection of 11 studies targeting patients with clinical or pathological stages T1 and T2 and reporting the clinical impact of CTC. The results of this search show encouraging data toward the use of CTC in patients with early-stage cancer. However, they also highlight the lack of standardized methods providing a highly sensitive and specific approach for the detection of prostate-derived CTC.

Keywords: circulating tumor cells (CTC); liquid biopsy; prostate cancer (PCa).

PubMed Disclaimer

Conflict of interest statement

Professor Patrizia Paterlini-Brechot is co-inventor of ISET® patents belonging to University Paris Descartes, INSERM and Assistance Publique Hopitaux de Paris, exclusively licensed to Rarecells Diagnostics, France. This author does not receive payments from Rarecells Diagnostics. The present study was conducted independently by academic research teams.

References

    1. Pernar C.H., Ebot E.M., Wilson K.M., Mucci L.A. The Epidemiology of Prostate Cancer. Cold Spring Harb. Perspect. Med. 2018;8 doi: 10.1101/cshperspect.a030361. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68:7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. Daniyal M., Siddiqui Z.A., Akram M., Asif H.M., Sultana S., Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac. J. Cancer Prev. 2014;15:9575–9578. doi: 10.7314/APJCP.2014.15.22.9575. - DOI - PubMed
    1. Cancer of the Prostate—Cancer Stat Facts. [(accessed on 31 May 2019)]; Available online: https://seer.cancer.gov/statfacts/html/prost.html.
    1. Jahn J.L., Giovannucci E.L., Stampfer M.J. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int. J. Cancer. 2015;137:2795–2802. doi: 10.1002/ijc.29408. - DOI - PMC - PubMed